When was Farapulse founded?

Farapulse was founded in 2014 and raised its 1st funding round 1 year after it was founded.

Where is Farapulse located?

Farapulse is headquartered in Menlo Park, United States.

How many employees does Farapulse have?

As of Jun 30, 2026, the latest employee count at Farapulse is 7.

Is Farapulse a funded company?

Farapulse is a funded company, having raised a total of $36.3M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Oct 13, 2015.

When was the latest funding round of Farapulse?

Farapulse's latest funding was a $***** Grant (prize money) round on Mar 01, 2021, with participation from 1 investor. Its primary sector is Cardiac and Vascular Disorders. In United States, the Cardiac and Vascular Disorders sector has seen $1.05B in funding in 2026 to date.

Where does Farapulse rank among its competitors?

Farapulse ranks 8th amongst 19 active competitors, of which 12 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Pulsecare Medical Technology, which secured $14M in Nov, 2025.

Who are the top competitors of Farapulse?

Farapulse's top competitors include Kardium, Galvanize and Field Medical. Among them, Pulsecare Medical Technology secured the most recent funding round in November, 2025.

Farapulse - 2026 Company Profile, Funding & Competitors

Farapulse is a series C company based in Menlo Park (United States), founded in 2014. It operates as an Advanced cardiac ablation solutions for atrial fibrillation treatment. Farapulse has raised $36.3M in funding from Boston Scientific and F-Prime Capital. The company has 19 active competitors, including 12 funded and 3 that have exited. Its top competitors include companies like Kardium, Galvanize and Field Medical.

Company Details

Advanced cardiac ablation solutions for atrial fibrillation treatment. This company specializes in minimally invasive cardiac ablation technology, specifically Pulsed Field Ablation (PFA), designed to treat atrial fibrillation (AFib). Their system precisely targets the source of irregular heartbeats using quick pulses of electrical energy, aiming to provide effective and safe treatment options when medications are insufficient. The technology seeks to minimize damage to surrounding areas, offering a potential alternative to traditional thermal ablation methods. They focus on improving patients' lives by reducing AFib symptoms and the need for long-term medication. The company provides resources and support for both healthcare professionals and patients, including educational materials and a center locator.

Website: www.farapulse.com/us/en/home.html
Social
Email ID: *****@farapulse.com
Phone Number: +1 **********

Key Metrics

Founded Year

2014

Location

Menlo Park, United States

Stage

Series C

Total Funding

$36.3M in 6 rounds

Latest Funding Round

Grant (prize money), Mar 01, 2021, $*****

Investors

Boston Scientific & 4 more

Ranked

8^th among 19 active competitors

Employee Count

7 as on Jun 30, 2026

Similar Companies

Kardium & 17 more

View Farapulse's full profile

Farapulse has raised a total funding of $36.3M over 6 rounds. Its first funding round was on Oct 13, 2015. Its latest funding round was a Grant (prize money) round on Mar 01, 2021 for $*****. 1 investor participated in its latest round. Farapulse has 5 institutional investors.

Here is the list of recent funding rounds of Farapulse:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 01, 2021	2185029	Grant (prize money)	3665346	4491544	7435616	9401879
Sep 21, 2020	9587793	Series C	6883331	4875920	8377406	6329718
May 31, 2018	1384076	Series B	7006462	3828342	1538547	9691253

Access funding benchmarks and valuations. Sign up today!

View details of Farapulse's funding rounds and investors

Farapulse's employee count trend

Farapulse has 7 employees as of Jun 26. Here is Farapulse's employee count trend over the years:

Uncover Farapulse's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Farapulse include Kardium, Galvanize and Field Medical. Here is the list of Top 10 competitors of Farapulse, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Kardium 2007, Burnaby (Canada), Series C	Developer of ablation device for atrial fibrillation	$471M	Fidelity Investments, T. Rowe Price & 10 others	65/100
2nd	Galvanize 2020, San Carlos (United States), Series C	Developer of pulsed electric field systems for various medical indications	$210M	Fidelity Investments, Sofinnova Partners ... & 11 others	58/100
3rd	Field Medical 2022, Encinitas (United States), Series B	Developer of device for the treatment of heart arrhythmia conditions	$89M	BioStar Capital, Cue Growth Partners	56/100
4th	Pulse Biosciences 2014, Burlingame (United States), Acquired	Developer of a platform technology called Nano-Pulse Electro-Signaling	$8M	MDB Capital, Sea Purity Investments & 1 others	50/100
5th	Pulsecare Medical Technology 2021, Shenzhen (China), Series A	Developer of medical device solutions for heart and vascular care	$14M	Oriza Holdings, Loayal Valley Capital & 3 others	50/100
6th	Affera 2014, Boston (United States), Acquired	Developer of devices to treat heart rhythm disorders	-	Innogest Capital, Bain Capital Life Sciences ... & 4 others	47/100
7th	Argá Medtech 2020, Epalinges (Switzerland), Series B	Developer of medical devices for treating cardiac arrhythmias	$58.5M	Advent Life Sciences, Earlybird & 1 others	45/100
8th	Farapulse 2014, Menlo Park (United States), Series C	Advanced cardiac ablation solutions for atrial fibrillation treatment	$36.3M	F-Prime Capital, Eight Roads Ventures & 3 others	42/100
9th	EnChannel Medical 2020, Ladera Ranch (United States), Series B	Developer of medical device for cardiac disorders	$110M	LAV, DragonBall Capital & 2 others	39/100
10th	AtriAN 2017, Galway (Ireland), Seed	Developing the device that targets to atrial fibrillation	$2.56M	Western Development Commission, Mayo Clinic Ventures ... & 4 others	34/100